NEXICLON XR provides the antihypertensive clinical benefits of immediate-release clonidine in a convenient once-daily, extended-release tablet1.
NEXICLON XR was studied in an open-label crossover, force titration, partially randomized trial in patients with mild and moderate essential hypertension who were on two or fewer antihypertensive medications. The trial was designed to compare steady-state exposures between the NEXICLON XR and clonidine immediate-release tablets. There were up- and down-titration phases. There was no washout period between phases or treatments.1
Following single doses of NEXICLON XR 0.17 mg, clonidine means (S.D.) peak plasma concentrations of 0.49 (+/- 0.09) ng/mL occurred at 7.8 (+/- 1.7) hours. The plasma half-life of clonidine was 13.7 (+/- 3.0) hours. There was no effect of food on the pharmacokinetic parameters.1
In the multi-dose study, mild to moderate hypertensive patients were randomized to ER and BID IR clonidine formulations. The following plot shows the sitting blood pressure values for each treatment group at Day 22.
- NEXICLON XR [prescribing information]. Athens, GA: Athena Bioscience LLC; 2021.